poisar

Stocks · News reference

Elicio Therapeutics Points To Durable Responses As It Maps Next Steps For Lead Cancer Drug

Vandana Singh

Elicio shares complete response data for ELI-002 7P in KRAS pancreatic cancer and plans combination studies after mixed Phase 2 results.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

BMYELTX
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Na

    Will Camzyos' Long-Term Benefits Strengthen BMY's Growth Outlook?

    Bristol Myers Squibb's Camzyos demonstrated durable reductions in LVOT obstruction over five years with 97.4% of patients achieving target gradients. Sales surged 74% year-over-year to $729 million in H1 2026. The company seeks FDA approval for adolescents with a decision expected by September 30, 2026. However, competition is intensifying with Cytokinetics' Myqorzo approved in December 2025 and Edgewise Therapeutics advancing EDG-7500 in clinical trials.

    BMYCELGRCYTKEWTX
  3. Prosper Junior Bakiny

    BioNTech vs. Moderna: Which Is the Better Cancer Vaccine Stock to Buy Now?

    BioNTech and Moderna, both mRNA vaccine pioneers during the pandemic, are now pivoting to cancer vaccines as COVID revenue declines. Moderna is favored due to stronger recent clinical progress, including positive phase 3 results for its personalized cancer vaccine intismeran autogene and FDA approval for mFLUSIVA flu vaccine. While BioNTech has a deep pipeline including pumitamig, it has yet to deliver comparable phase 3 wins. Moderna's $61.2 billion market cap reflects investor confidence in its near-term commercialization prospects versus BioNTech's $26 billion valuation.

    BNTXMRNAMRKBMYCELGR
  4. Not Specified

    Cancer Survivors to Swim 28.5 Miles Around Manhattan to Fund Cancer Care in Kenya

    A team of swimmers, including cancer survivors, will swim 28.5 miles around Manhattan on September 10, 2026, to raise funds and awareness for Catholic Medical Mission Board's (CMMB) efforts to equip the Phangisile Mtshali Cancer Center in Kenya with chemotherapy ports and treatment equipment. The initiative addresses a critical shortage of safe chemotherapy delivery devices in Kitui County, Kenya.

    BMYCELGR
  5. Na

    Elicio Therapeutics to Participate at the H.C. Wainwright 28th Annual Global Investment Conference

    Elicio Therapeutics announced that its CEO Robert Connelly and Chief Scientific Officer Pete DeMuth will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026. The clinical-stage biotech company is developing next-generation immunotherapies for KRAS-driven cancers, with its lead program ELI-002 7P targeting the most common KRAS mutations found in approximately 25% of solid tumors.

    ELTX